Incidence of dynamic seroconversion in subjects received the first dose of the SARS-COV-2 vaccine (AstraZeneca, Moderna and Pfizer) in Kinshasa, Democratic Republic of Congo: prospective cohort study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mukenge Eric Kasongo, Sumbu Blaise Matondo-Manzambi, Nkodila Aliocha Natuhoyila, Muwonga Jeremie Masidi, Makulo Jean-Robert Rissassi, Ngole Mamy Zita, Bepouka Ben Izizag, Longokolo Murielle Mashi, Kamwiziku Guyguy, Situakibanza Hippolyte Nanituma, Kayembe Jean-Marie Ntumba, Longo-Mbenza Benjamin, Mvumbi George Lelo, Buassa-Bu-Tsumbu Baudouin, Makangara Jean Claude, Mashinda Désire Kulimba, Mafuta Eric Musalu, Mangala Donatien Sonzi, Nkanga Mireille Nganga, Ilunga Gustave Ntita, Nkunda Fonce Tshibawu, Lengo Christian Nsimba, Ahuka Steve Mundeke
Аннотация
METHODS: This was a prospective study recruiting 918 subjects vaccinated at the Cliniques Universitaires de Kinshasa between 19 April and 14 August 2021. Sociodemographic, haematological, biochemical and serological data were collected. Cox proportional hazards were used to identify predictors of seroconversion with a threshold of p < 0.05.
RESULTS: Of the 918 vaccinated individuals, 69.3% were men with a mean age of 47.4 ± 16.0 years. The incidence of seroconversion at last follow-up was 3.00 per 100 P-D. Patients receiving Pfizer (aRR: 3.19; 95% CI: 2.62-3.88) and Modern (aRR: 1.91; 95% CI: 1.60-2.29) vaccines, men (aRR: 2.03; 95% CI: 1.89-3.20), those with comorbidities (aRR: 2.38; 95% CI: 1.89-3.21); subjects with normal creatinine (aRR: 2.08; 95% CI: 1.88-3.32) and normal ALT (aRR: 3.04; 95% CI: 1.89-4.22) were the factors independently predicting seroconversion.
CONCLUSION: The vaccines used had conferred significant immunity on subjects upon receipt of the first dose. This immunity appears to be greater when using the mRNA vaccine than when using the inactivated vaccine.